BIS News and Press, ProShares UltraShort Nasdaq Biotechnology From 02/21/20

High drug prices will, again, be a key issue in the 2020 Presidential campaign considering that President Trump has made scant progress on the matter despite much rhetoric. More news on: Eli Lilly and Company, Merck & Co., Inc., Amgen Inc., Healthcare stocks news, , News on ETFs, R...

It may seem counter-intuitive that during a year in which the world economy recorded its weakest performance since the global financial crisis, asset prices delivered fantastic returns across the board. Somewhat ironically, today’s situation is the exact opposite of the one we desc...

Faced with pushback from multiple fronts over high drug prices, biopharmaceutical firms are experimenting with new ways to get paid for their priciest offerings, mostly biologics, in a report from the WSJ. More news on: Alnylam Pharmaceuticals, Inc., Sanofi, Novartis AG, Healthcare stock...

The new budget proposed by California Governor Gavin Newsom includes a plan to allow the state to contract with generic drug makers to provide medicines to all Californians. He believes that the government's purchasing power may be sufficient to cut drug prices to the state's 40M residents...

Results from a new study showed that end-of-year drug approvals by the FDA are linked to more hospitalizations, life-threatening events and deaths, a rate about twice as high as medicines approved earlier in the year. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology,...

Reuters reports that pharmaceutical companies, including Pfizer (NYSE: PFE ), GlaxoSmithKline (NYSE: GSK ) and Sanofi (NASDAQ: SNY ), are planning to raise prices on more than 200 medicines in the U.S. tomorrow. More news on: Pfizer Inc., GlaxoSmithKline plc, Sanofi, Healthcare stocks ne...

By a 230-192 margin, the U.S. House of Representatives has passed legislation , championed by Speaker Nancy Pelosi, aimed at corralling spiralling drug costs. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology, Tekla World Healthcare Fund, ARK Genomic Revolution Multi-Se...

The Institute for Clinical and Economic Review (ICER), a Boston-based nonpartisan nonprofit with no policy-making role, has emerged as a major influencer on pricing by drugmakers. More news on: Sanofi, Regeneron Pharmaceuticals, Inc., Amgen Inc., Healthcare stocks news, News on ETFs, ...

In a statement , the FDA says chronic shortages of certain medicines in the U.S. have not produced the expected responses from drugmakers that traditional economics predict, specifically, increasing prices to reflect a supply/demand imbalance aimed at achieving profitable production to sati...

On a strict party line basis, the U.S. House of Representatives' Education and Labor Committee voted 27-21 backing Speaker Nancy Pelosi's drug pricing bill (H.R. 3). All 27 Dems voted in favor and all 21 GOP members voted against. More news on: Pfizer Inc., Merck & Co., Inc., Bristol...